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Paclitaxel is among the most widely used anticancer drugs and is known to cause a dose-
limiting peripheral neurotoxicity, the initiating mechanisms of which remain unknown. Here,
we identified the murine solute carrier organic anion–transporting polypeptide B2
(OATP1B2) as a mediator of paclitaxel-induced neurotoxicity. Additionally, using
established tests to assess acute and chronic paclitaxel-induced neurotoxicity, we found
that genetic or pharmacologic knockout of OATP1B2 protected mice from mechanically
induced allodynia, thermal hyperalgesia, and changes in digital maximal action potential
amplitudes. The function of this transport system was inhibited by the tyrosine kinase
inhibitor nilotinib through a noncompetitive mechanism, without compromising the
anticancer properties of paclitaxel. Collectively, our findings reveal a pathway that explains
the fundamental basis of paclitaxel-induced neurotoxicity, with potential implications for its
therapeutic management.
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Introduction
The tubulin poison paclitaxel is among the most widely used drugs 
in the treatment of a variety of solid tumors, including early-stage 
and metastatic breast cancer (MBC). Paclitaxel induces a chronic, 
dose-dependent sensory peripheral neuropathy that is character-
ized by tingling, numbness, increased sensitivity to cold and touch, 
and burning pain of the distal extremities, and this side effect 
occurs with an incidence of up to 70%–80% in patients with MBC 
(1). With cumulative dosing, the painful symptoms increase in 
severity and can persist for years (2), or even cause a lifelong func-
tional impairment that impacts quality of life (3). This toxicity may 
also lead to therapy cessation, which may impact clinical outcomes.
The mechanistic basis of this side effect remains uncertain 
(4), although prior studies have demonstrated that paclitaxel 
induces injury to sensory neurons, morphological and biochemi-
cal alterations in dorsal root ganglia (DRG) satellite cells, hyper-
plasia/hypertrophy of macrophages in the peripheral nervous sys-
tem, and increases microglial and astrocyte activation within the 
spinal cord (5, 6). Paclitaxel also causes an acute pain syndrome 
that develops within 1–3 days of paclitaxel administration, and that 
resolves within 1 week. This acute syndrome is possibly caused by 
activation of Toll-like receptor 4 (TLR4) in the spinal dorsal horn 
and DRG (7), the main site of paclitaxel uptake within the nervous 
system (8). Interestingly, prospective clinical studies have dem-
onstrated that patients experiencing the acute pain syndrome fol-
lowing the first administration of paclitaxel are those who subse-
quently develop chronic neuropathy (9).
Over the last 3 decades, various approaches have been pro-
posed to predict, prevent, and/or treat paclitaxel-induced periph-
eral neuropathy (10). The predictive strategies have predomi-
nantly focused on the search for hereditary biomarkers that could 
identify patients at increased risk of toxicity through candidate 
gene or genome-wide association studies (5, 11, 12). However, the 
findings from these studies done to date have identified nonover-
lapping single or pathway biomarker associations that preclude 
immediate clinical implementation. In addition, the decision to 
act on a toxicity biomarker is hampered in many diseases by the 
lack of available alternative treatments to replace paclitaxel and/
or the need for a patient-tailored reduction in the paclitaxel dose to 
prevent toxicity, which will have negative effects on disease man-
agement. Against this background, the development of preventa-
tive strategies that could effectively afford tissue protection dur-
ing paclitaxel treatment is urgently needed. Although preventative 
interventions have been proposed, many of these have not been 
evaluated in animal models or humans. Moreover, to date there 
have been more than 40 randomized controlled clinical trials of 
agents to prevent or treat peripheral neuropathy, and these trials 
have generally failed to provide convincing evidence for a clini-
cally beneficial agent (13). Here, we report that paclitaxel accu-
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Role of OATP1B2 in paclitaxel-induced neuropathy. To determine 
the role of OATP1B2 in paclitaxel-induced neuropathy in vivo, we 
first performed comparative pharmacokinetic studies of paclitaxel 
in wild-type mice and OATP1B2–/– mice (19). These studies demon-
strated that the average systemic exposure, measured by the area 
under the curve (AUC) in plasma, after the administration of a clin-
ically relevant dose of paclitaxel was only modestly increased in 
OATP1B2–/– mice (Figure 2A), whereas the observed terminal half-
lives of paclitaxel were not dependent on mouse genotype (Supple-
mental Table 2). This suggests that, from a pharmacokinetic per-
spective, these mice are an appropriate model of human patients 
(18), with the knowledge that potentially genotype-dependent 
differences in systemic exposure are unlikely to directly affect the 
extent to which paclitaxel can induce peripheral neuropathy. We 
also found that, as reported previously with docetaxel (15), genetic 
deficiency of OATP1B2 in mice results in decreased liver uptake of 
paclitaxel, as well as decreased uptake into DRG (Figure 2B).
This mouse model was subsequently used to first determine 
the role of OATP1B2 in paclitaxel-induced neuropathy on the basis 
of a test that evaluates mechanical allodynia, a widely used mea-
sure of acute paclitaxel-induced neuropathy in mice (2, 7, 20). Our 
results using this test suggest that wild-type and OATP1B2–/– mice 
do not show intrinsic differences in sensitivity to mechanical stim-
uli at baseline (Figure 2C). However, wild-type mice experienced 
significantly increased sensitivity to mechanical stimulation after 
administration of paclitaxel, where the force to induce a response 
decreased by more than 50% within 2 days after administration of 
mulates in cells through a process that is mediated by OATP1B2, 
that paclitaxel induces neurotoxicity in mice in an OATP1B2-
dependent manner, and that these phenotypes can be reversed by 
a pretreatment with the tyrosine kinase inhibitor (TKI), nilotinib.
Results
OATP1B2 as a putative paclitaxel transporter in mouse neurons. 
Paclitaxel is known to extensively accumulate in DRG and can 
be taken up into cells via a process mediated by specific organic 
anion–transporting polypeptides (OATPs), in particular OAT-
P1B1 (SLCO1B1) and OATP1B3 (SLCO1B3) in humans (14–17) 
and OATP1B2 (Slco1b2) in rodents (18). To directly demonstrate 
a contribution of this transport system to paclitaxel toxicity, we 
used a mouse model with and without deletions of OATP1B2 
(OATP1B2–/– mice). Analysis of livers and DRG from wild-type 
mice revealed that OATP1B2 is highly expressed in both tissues 
as based on immunoblotting (Figure 1A) and immunofluores-
cence in DRG (Figure 1B). The expression of 84 ATP-binding 
cassette (ABC) transporter and solute carrier (SLC) genes (Sup-
plemental Table 1; supplemental material available online with 
this article; https://doi.org/10.1172/JCI96160DS1) was not sub-
stantially changed in DRG from OATP1B2–/– mice compared with 
tissues obtained from wild-type animals, with the exception of 
a downregulation of transcripts of the related transporter OAT-
P2B1 (Figure 1C). The functional impact of this observation is 
likely limited, considering that paclitaxel was not found to be a 
transporter substrate of OATP2B1 (Figure 1D).
Figure 1. Phenotypic characterization of OATP1B2–/– mice. (A) Comparative expression of OATP1B2 protein in liver and DRG at baseline of wild-type (WT) and 
OATP1B2–/– (–/–). (B) Detection of OATP1B2 by immunofluorescence in DRG of wild-type and OATP1B2–/– mice. OATP1B2 is depicted by yellow fluorescence, 
whereas DNA is depicted in blue (DAPI). Scale bars: 50 μm. (C) Comparative expression of 84 transporter genes in DRG at baseline of wild-type and OATP1B2–/– 
mice (n = 3 samples per group). Each symbol represents an average reading for a single gene, the solid line is the line of identity, and the dotted lines represent 
the 95% confidence intervals. The colored symbol represents the transporter gene for OATP2B1 (SLCO2B1). (D) Lack of paclitaxel transport by OATP2B1 in 
HEK293 cells transfected with an empty vector (VC) or OATP2B1 (2.5 μM; 5-minute incubations). Overexpression of the transporter was confirmed by evaluat-
ing the uptake of estrone-3-sulfate (E2S). Data represent the mean of triplicate observations from experiments performed on 2 separate occasions, and are 
expressed as average percentage of uptake values in cells transfected with an empty vector (VC) with error bars representing SD. *Denotes significant differ-
ences from VC (P < 0.05), and NS denotes not significant, as evaluated with an unpaired 2-sided Student’s t test with Welch’s correction.
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(23), we performed a screen with FDA-approved TKIs and con-
firmed that several of these agents inhibited OATP1B1 function 
by at least 75% using 8-(2-[fluoresceinyl]-aminoethylthio)-
adenosine-3′,5′-cyclic monophosphate (8Fc-A) (Figure 3A) or 
estradiol-17β-ᴅ-glucuronide (E2G) (Figure 3B) as prototypical 
test substrates. Nilotinib, an inhibitor of the Bcr-Abl tyrosine 
kinase used for the treatment of patients with chronic myeloid 
leukemia, was the most potent inhibitor of OATP1B1, in line 
with several recent reports (23, 24). Nilotinib was found to influ-
ence OATP1B1 function at concentrations that can be achieved 
clinically (IC50, ~1 μM) (Figure 3C), and was also able to inhibit 
OATP1B3 (Figure 3D). Since nilotinib is itself a poor substrate 
of OATP1B1 and OATP1B3 (25), the observed interactions are 
most likely the result of a noncompetitive inhibitory mecha-
nism (Supplemental Figure 2). As anticipated based on the high 
degree of sequence homology between human and rodent OAT-
P1B-type transporters, their similarity in membrane localiza-
tion, and largely overlapping substrate and inhibitor specificity 
(26), we found that nilotinib was also able to inhibit the func-
tion of OATP1B2 (Figure 3E). In addition, we confirmed that the 
plasma levels of paclitaxel were not affected by pretreatment 
with nilotinib (Figure 3F), suggesting that nilotinib is unlikely to 
affect paclitaxel-related neurotoxicity phenotypes due to chang-
es in systemic clearance (Supplemental Table 3).
paclitaxel, persisted for a week, and then returned to baseline val-
ues by 2 weeks. This phenotype is likely causally related to pacli-
taxel itself, since its main liver metabolites 6α-hydroxy-paclitaxel, 
3′-p-hydroxy-paclitaxel, and 6α,3′-p-dihydroxy-paclitaxel (21) 
were found to have significantly diminished potential to alter 
sensitivity to mechanical stimuli compared with the parent drug 
(Supplemental Figure 1).
In contrast to wild-type mice, OATP1B2–/– mice exposed to 
paclitaxel showed no significant change in sensitivity to mechanical 
allodynia (Figure 2C). These results suggest that OATP1B2–/– mice 
are protected from acute paclitaxel-induced neuropathy similar 
to that observed in animals receiving only the paclitaxel vehicle. 
Similar observations were made with paclitaxel administered over 
a 4-week period (Figure 2D). Following this chronic regimen, we 
found that OATP1B2–/– mice were also protected against paclitaxel-
induced thermal hyperalgesia (Figure 2E) and changes in digital 
nerve maximal action potential amplitude (AMP) (Figure 2F). In 
support of a functional involvement of OATP1B2 in the paclitaxel-
induced toxicity, it is noteworthy to point out that the taxane caba-
zitaxel, the usage of which is very rarely associated with peripheral 
neuropathy (22), is not transported by OATP1B-type carriers (18).
Identification of nilotinib as an inhibitor of OATP1B-type 
transporters. Because several members of the class of TKIs were 
previously found to potently inhibit OATP1B1 function in vitro 
Figure 2. Influence of OATP1B2 loss on paclitaxel disposition and neurotoxicity. (A) Plasma concentration-time curves and (B) tissue distribution ratios 
of paclitaxel after an i.v. dose of 10 mg/kg. Mechanical allodynia after 1 or 2 doses of paclitaxel (10 mg/kg, i.v.; time 0 and 72 hours) (C), or 4 doses (70 mg/
kg, i.v. once weekly) (D). Thermal hyperalgesia (E) and changes in digital nerve maximal action potential amplitudes (F) after 4 doses of paclitaxel (70 
mg/kg, i.v.). All data represent mean values (bars) and SD (error bars) for disposition or SEM for toxicity, using n = 4 (disposition) or n = 4–24 (toxicity) per 
group. *Denotes significant differences from baseline and OATP1B2–/– mice (P < 0.05), as evaluated with an unpaired 2-sided Student’s t test with Welch’s 
correction or a 1-way analysis of variance with a Dunnett post-hoc test (B).
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by nilotinib. The success of such a combination therapy would 
depend on the selected dosing/scheduling strategy and on the 
expression status of OATP1B-type transporters in cancer cells. 
To gain preliminary insights, we evaluated the transcriptional 
profiles of the OATP1B1 and OATP1B3 genes in human tumor 
specimens using normalized RNA sequencing data from 29 indi-
vidual cancer cohorts from The Cancer Genome Atlas (TCGA). 
This analysis indicated that the transporters are expressed at low 
levels in samples associated with the main paclitaxel indications 
such as MBC (Supplemental Figure 5). In agreement with previ-
ous studies (28), we were unable to detect appreciable levels of 
OATP1B1 and OATP1B3 in 48 additional human MBC samples, 
irrespective of disease stage or receptor status (Supplemental 
Table 4). This suggests that OATP1B1 and OATP1B3 represent 
selective uptake transporters that, when inhibited, may reduce 
cellular toxicity without altering the treatment efficacy of pacli-
taxel against tumors. Consistent with this supposition, we found 
that the cellular uptake and cytotoxicity of paclitaxel was not sub-
stantially altered by nilotinib in MBC cell lines (Table 1 and Sup-
plemental Figure 6). These results suggest that paclitaxel can be 
taken up into breast cancer cells by one or more distinct carriers 
independently of OATP1B1 or OATP1B3, and that these presently 
unknown carriers are insensitive to nilotinib-mediated inhibition.
Nilotinib protects against paclitaxel-induced neuropathy. Next, we 
found that pretreatment of mice with oral nilotinib protected against 
acute and chronic forms of paclitaxel-induced mechanical allodynia 
in wild-type mice, and that nilotinib administration had no effect 
in OATP1B2–/– mice (Figure 4, A and B). Partial protection against 
paclitaxel-induced mechanical allodynia could also be afforded by 
rifampin, a known inhibitor of OATP1B2 (27), and by pazopanib, 
another TKI identified from our screen, but not sorafenib, a TKI that 
does not inhibit OATP1B2 in vivo (23) (Supplemental Figure 3). Simi-
larly to the acute toxicities, nilotinib was found to effectively reverse 
paclitaxel-associated changes in thermal hyperalgesia (Figure 4C) 
and digital AMP (Figure 4D). Consistent with these observations, we 
found that administration of nilotinib to mice could inhibit the phos-
phorylation of the kinase c-Abl, a known target of nilotinib, in both 
liver and DRG (Supplemental Figure 4). These experiments have not 
only provided the initiating molecular mechanism responsible for the 
pathogenesis of paclitaxel-induced peripheral neuropathy, but have 
also provided proof of principle that targeting of OATP1B-type trans-
porters could be an effective neuroprotective strategy (Figure 5).
Nilotinib as an adjunct to paclitaxel therapy. Although combin-
ing paclitaxel with nilotinib could possibly reduce the incidence 
and severity of drug-induced toxicity, it is important to establish 
that the anticancer efficacy of paclitaxel is not compromised 
Figure 3. Inhibition of OATP1B-type transporters by nilotinib. Inhibition of OATP1B1 function by tyrosine kinase inhibitors (TKIs) in vitro (10 μM; 15-min-
ute preincubation), using 8-(2-[fluoresceinyl]-aminoethylthio)-adenosine-3′,5′-cyclic monophosphate (8Fc-A) (A) and estradiol-17β-D-glucuronide (E2G) 
(B) as OATP1B1 substrates in transfected HEK293 cells. (C) Concentration-dependent inhibition of OATP1B1 function by nilotinib using 8Fc-A (2 μM; 15-min-
ute uptake) as a substrate. Inhibition of OATP1B3 (D) and OATP1B2 (E) by nilotinib using 2 different substrates (2 μM; 15-minute uptake). Data (n = 6–9 
per group) were normalized to substrate uptake in the absence of nilotinib, and corrected for nonspecific uptake in cells transfected with an empty vector. 
(F) Plasma concentration-time curves of paclitaxel after paclitaxel administration (10 mg/kg) pretreated with nilotinib (100 mg/kg; p.o.) or vehicle (n = 5 
per group). All data represent mean values (bars or symbols) and SD (error bars). *Indicates significant differences from the corresponding vehicle control 
group (P < 0.05), as evaluated with an unpaired 2-sided Student’s t test with Welch’s correction.
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of the DRG neuronal axons (8). Moreover, previous studies have 
demonstrated that the cellular uptake of paclitaxel and structurally 
related taxanes such as docetaxel occurs via a facilitated transport 
mechanism (16). Consequently, distribution patterns and pathologi-
cal changes following paclitaxel administration are restricted to cells 
in organs capable of transporting paclitaxel from the blood into cells. 
Indeed, transmembrane transport of taxanes is now widely acknowl-
edged to be mediated by specific OATPs. In particular, we previously 
reported that paclitaxel and docetaxel are transported substrates of 
human OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3) (14–17), as 
well as the single functional homolog OATP1B2 (Slco1b2) in mice (18) 
and rats (18, 29). These findings have been independently verified 
(30–34), and are consistent with in vitro studies that have identified 
paclitaxel as a potent inhibitor of OATP1B1- (35, 36) and OATP1B3-
mediated transport (35, 37, 38). However, none of the other known 
9 human OATPs or other rodent OATPs are capable of transporting 
paclitaxel (39), and similar results have been obtained with docetaxel 
(40). These studies highlight the notion that OATPs capable of trans-
porting paclitaxel need to be expressed in tissues such that the drug 
can exert cellular injury. We previously reported that OATP1B2 is 
detectable in mouse DRG (41), and an independent study evaluating 
all 15 mouse OATPs confirmed expression of OATP1B2 in the mem-
brane of perikarya and neurites of cultured primary murine neurons 
(42). Our present identification of high OATP1B2 protein expression 
in DRG is thus consistent with these prior observations.
The demonstration that OATP1B2 plays an important role in 
a clinically relevant paclitaxel-related toxicity provides a com-
pelling rationale for the development of translational interven-
tions for paclitaxel-containing regimens in patients involving 
the use of specific inhibitors of these carriers. Such agents would 
ideally have high potency, high specificity, low drug-drug inter-
action potential, intrinsic antitumor properties, favorable phar-
maceutical properties, and nonoverlapping toxicity profiles. We 
hypothesized that the class of TKIs is of particular interest in this 
context, as these agents have many of the above features, and 
several members of the class have been found to potently inhibit 
various drug transporters (43). The ultimate identification of 
nilotinib as an inhibitor of OATP1B2, without being itself a trans-
ported substrate, is consistent with a recent report suggesting 
Discussion
The current study identified OATP1B-type organic anion trans-
porters as important, previously unrecognized contributors to 
paclitaxel-induced damage to the peripheral nervous system. 
In particular, our results show that mice with a deficiency of the 
murine ortholog transporter OATP1B2 are partially protected 
from acute and chronic paclitaxel-induced 
neuropathy. In addition, we found that 
nilotinib, an FDA-approved TKI for the 
treatment of certain leukemias, is a potent 
inhibitor of OATP1B-type transport, and 
that concomitant use of nilotinib with pacli-
taxel abrogates peripheral neuropathy by 
inhibiting this drug transport mechanism.
We originally hypothesized that pacli-
taxel-induced peripheral neuropathy is initi-
ated by extensive uptake of paclitaxel in the 
nervous system. This idea is supported by 
the finding that paclitaxel has easy access 
to DRG where it extensively accumulates, 
and that detectable levels of paclitaxel can 
be observed in the sciatic nerve and spinal 
cord, presumably owing to transport along 
the centrifugal and centripetal branches 
Figure 4. Influence of nilotinib on paclitaxel-induced neurotoxicity. 
Mechanical allodynia after 1 dose of paclitaxel (Pac; 10 mg/kg, i.v.) (A), 
or 4 doses (70 mg/kg, i.v. once weekly) (B) in the presence or absence of 
pretreatment with nilotinib (Nil; 100 mg/kg; p.o.). Thermal hyperalgesia (C) 
and changes in digital nerve maximal action potential amplitudes (D) after 
4 doses of paclitaxel with or without nilotinib pretreatment. All data rep-
resent mean values (bars) and SEM (error bars), using n = 4–24 per group. 
*Denotes significant differences from other groups (P < 0.05), as evaluated 
with a 1-way analysis of variance with a Dunnett post-hoc test.
Figure 5. Proposed model of paclitaxel-induced injury to the peripheral nervous system. Paclitaxel 
enters the nervous system through OATP1B2, ultimately leading to peripheral neuropathy (left), and 
these effects can be prevented by the OATP1B2 inhibitor nilotinib (right).
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potent in vitro inhibition by nilotinib of OATP1B-type carriers at 
concentrations that are predicted to have potential in vivo signif-
icance (44). The mechanism by which nilotinib affects OATP1B2 
function requires further investigation.
Nilotinib was originally developed as an inhibitor of the Bcr-
Abl tyrosine kinase and has been used clinically as a once/twice 
daily oral tablet for the treatment of patients who are in the chron-
ic and accelerated phases of Philadelphia-chromosome-positive 
chronic myeloid leukemia. Although the combination of nilotinib 
and paclitaxel has not been explored clinically in any disease, 
nilotinib has pharmaceutical and pharmacological features that 
suggest it might be an excellent modulator of paclitaxel toxicities. 
These include good oral absorption, a relatively slow systemic 
clearance, and a long half-life (45), thus ensuring sufficiently high 
and persistent local drug levels. Interestingly, high-dose TKI pulse 
exposure — rather than the more commonly used chronic low-
dose schedules involving daily dosing — is becoming an increas-
ingly frequently applied concept in the treatment of cancer (46), 
and the clinical experience with such a strategy will ultimately 
allow easy translation of our proposed concept to use nilotinib as a 
transporter inhibitor in conjunction with paclitaxel-based chemo-
therapy in patients. We acknowledge that, while most side effects 
associated with nilotinib are mild, reversible, and easily managed, 
the drug’s prescribing information carries a black box warning 
for QT prolongation (47). It should be pointed out, however, that 
the median time from the start of nilotinib therapy using a con-
ventional chronic regimen (i.e., once or twice daily dosing with-
out interruption) to the onset of such QT events is greater than 
14 months (range, 2–68 months) (48). In our studies, we aim to 
interrogate the response of the peripheral nervous system to the 
nilotinib-paclitaxel combination following acute or intermittent 
exposure to the TKI. Therefore, we anticipate that nilotinib will 
not be intrinsically toxic in such combination therapy regimens.
The translational potential of a nilotinib-based intervention 
strategy to prevent paclitaxel toxicity is further supported by our 
observation that the TKI does not antagonize the 
cytotoxic effects of paclitaxel in the same 5 pre-
clinical models of MBC, as determined by an MTT 
assay in 2-dimensional culture. These findings 
are in line with previously reported synergistic in 
vitro effects of nilotinib and paclitaxel in models 
of ovarian cancer (49) and certain ABCB1-overex-
pressing tumors (50). Near the completion of our 
investigations, we became aware of an ongoing 
project, recently published (51), aimed at identi-
fying promising combinations of approved drugs 
with potent anticancer activity against a panel of 
60 human tumor cell lines for translation to clini-
cal trials. Strikingly, in that study, the nilotinib-
paclitaxel combination was identified as an exqui-
sitely active drug pair against breast cancer cell 
lines, resulting in tumor regressions in the MDA-
MB-468 xenograft model with no tumor regrowth 
observed for more than 80 days following the end 
of therapy (51). Although in vivo confirmation is 
required in patient-derived xenograft model sys-
tems that more faithfully represent the charac-
teristics of primary human MBC compared with xenografted cell 
lines (52), these combined initial observations indicate that com-
bining paclitaxel with TKIs such as nilotinib has the potential to 
simultaneously reduce toxicities and increase anticancer effects.
Collectively, we identified a previously unrecognized path-
way of paclitaxel-induced peripheral neurotoxicity that is medi-
ated by OATP1B-type transporters. The function of this transport 
system can be inhibited by nilotinib through a noncompetitive 
mechanism, without compromising the anticancer properties of 
paclitaxel in models of MBC. These findings not only shed light 
on the etiology of paclitaxel-induced neurotoxicity, but provide a 
rationale for the future development of new targeted interventions 
using transporter inhibitors to mitigate a debilitating side effect 
associated with paclitaxel.
Methods
In vitro transport studies. Human embryonic kidney (HEK293) cells 
(ATCC) transfected with OATP1B1, OATP1B3, or OATP1B2 have been 
described previously (15). The transporter nomenclature used through-
out is based on recent recommendations proposed by Hagenbuch and 
Stieger (53). The transporter-expressing cells were functionally charac-
terized by assessing the uptake of E2G (0.1 or 2 μM) by OATP1B1, OAT-
P1B3, and OATP1B2, and estrone-3-sulfate (2 or 2.5 μM) by OATP2B1. 
HEK293 cells overexpressing OATP2B1 were created by transfecting an 
empty pCMV6-entry vector or a construct containing OATP2B1 cDNA 
using Lipofectamine 3000 (Thermo Fisher Scientific), and cells were 
selected based on G418 resistance. Overexpression of transporters was 
confirmed using TaqMan probes (Applied Biosystems). HEK293 cells 
were maintained in DMEM supplemented with 10% heat-inactivated 
FBS, and routinely checked to ensure there was no mycoplasma con-
tamination (MycoAlert Detection Kit). Passages were kept to a mini-
mum and cells were not used beyond passage 30.
The cell culture conditions and details of accumulation experi-
ments for [3H]paclitaxel (specific activity, 25.6 Ci/mmol; Vitrax) were 
performed as described previously (15). Radioactivity was quantified 
Table 1. Influence of nilotinib on paclitaxel activity against breast cancer cellsA
Cell line Paclitaxel Nilotinib Pac + Nil (1 μM) Pac + Nil (5 μM)
MDA-MB-468 IC50 (nM) 22.8 4,830 9.06 4.37
Uptake (pmol/mg) 13.4 ± 1.40 N/A N/A 9.86 ± 3.24
MCF-7 IC50 (nM) 157 10,200 61.9 4.70
Uptake (pmol/mg) 6.04 ± 1.09 N/A N/A 4.25 ± 1.11
T-47D IC50 (nM) 85.9 3,710 33.9 <0.1
Uptake (pmol/mg) 8.96 ± 0.804 N/A N/A 6.71 ± 0.906
MDA-MB-231 IC50 (nM) 20.9 10,900 11.9 10.4
Uptake (pmol/mg) 5.87 ± 1.93 N/A N/A 4.67 ± 1.38
HS-578T IC50 (nM) 26.1 3,190 28.8 13.1
Uptake (pmol/mg) 13.6 ± 6.19 N/A N/A 11.9 ± 4.77
AAll data are presented as mean values and SD, using n = 6–8 per group. The cell growth 
inhibitory potential of paclitaxel (range, 0.00001–50 μM) or nilotinib (0.01–100 μM) was 
evaluated with an MTT assay using 72-hour continuous exposure. The cell growth inhibitory 
potential of paclitaxel (range, 0.01–100 μM) was also evaluated in the presence of nilotinib (1 
or 10 μM; 15-minute preincubation). Accumulation of paclitaxel (2 μM; 5-minute uptake) was 
determined in the presence or absence of nilotinib (15-minute preincubation with 10 μM or 
vehicle). IC50, half-maximum inhibitory concentration; Pac, paclitaxel; Nil, nilotinib.
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by liquid scintillation counting using an LS 6500 Counter (Beckman). 
Drug uptake results were normalized to total protein content and then 
to data obtained in cells carrying an empty vector plasmid, which was 
set to 100%. Preliminary experiments indicated that phenol red, a 
pH indicator in trypsin used to resuspend cultured cells, influenced 
OATP1B-mediated cellular uptake of taxanes, and therefore these 
studies were performed in phenol red–free conditions. The influence 
of TKIs (10 μM; 15-minute preincubation) on OATP1B1, OATP1B3, or 
OATP1B2 function was evaluated using E2G or 8Fc-A (Axxora LLC) as 
prototypical substrates.
Murine pharmacokinetic studies. Wild-type and OATP1B2–/– mice, 
both on a DBA/1LacJ background and between 8 and 12 weeks of 
age, were housed in a temperature-controlled environment with a 
12-hour light/dark cycle. These mice were provided by Richard B. 
Kim (Western University, London, Ontario, Canada) and Jeffrey L. 
Stock (Pfizer Inc., Groton, Connecticut, USA). All mice received a 
standard diet and water ad libitum. For pharmacokinetic studies, 
paclitaxel was formulated in Cremophor EL/ethanol (1:1, v/v; Taxol; 
Bristol-Myers Squibb). These solutions were diluted in normal saline 
and administered by i.v. bolus in the tail vein at a dose of 10 mg/kg. 
In select experiments, oral nilotinib (formulated in 0.5% hydroxypro-
pyl-methylcellulose in water) was administered 30 minutes before 
paclitaxel at a dose of 100 mg/kg. At select time points after pacli-
taxel administration, blood samples (30 μl each) were taken from 
individual mice at 3.5, 7.5, and 15 minutes from the submandibular 
vein using a lancet, and at 30 and 60 minutes from the retro-orbital 
venous plexus using a capillary. The total blood volume collected 
during the procedure from each mouse was 150 μl. A final additional 
blood draw was obtained at 120 minutes by cardiac puncture using a 
syringe and needle. Isoflurane was used as an anesthetic. All blood 
samples were centrifuged at 1,500 g for 5 minutes, and plasma was 
separated and stored at –80°C until analysis by a validated method 
based on reversed-phase liquid chromatography coupled to tandem 
mass-spectrometric detection (LC/MS/MS) using a previously pub-
lished procedure (54), with modifications (see below).
Livers and DRG were collected from the same animals at 120 min-
utes and, to prevent continuing metabolic activity, tissues were snap-
frozen using liquid nitrogen. All tissue specimens were stored at –80°C 
until further processing, as described previously (15). All organs were 
diluted in blank (drug-free) human plasma (1:4, w/v) in a 2-ml Eppen-
dorf vial. Next, a 5-mm stainless steel bead (Qiagen) was added, and 
the samples were homogenized with a TissueLyser (Qiagen), and pro-
cessed for 4 minutes at 40 Hz. Finally, the beads were removed and 
the homogenized samples were stored at –70°C until analysis by LC/
MS/MS. Noncompartmental pharmacokinetic parameters were calcu-
lated using WinNonlin 6.2 software (Pharsight), and drug levels in tis-
sues were corrected for contaminating plasma.
Determination of drug levels. Paclitaxel was quantified using LC/
MS/MS. Sample extracts were injected into an Alltima HP C18 HL 
3-μm column (50 × 2.1 mm internal diameter, Alltech Applied Sci-
ence) by a Waters 2795 Separation Module. The mobile phase for 
determination of paclitaxel was composed of acetonitrile and water 
containing formic acid (0.1% v/v), and was delivered using linear gra-
dient settings at a flow rate of 0.2 ml/min. Detection was performed 
with a MicroMass Quatro Micro triple-quadrupole mass spectrom-
eter (Waters) in the positive ion mode. The electrospray ionization 
was set at 3.8 kV and the cone voltage at 18 V. The dwell times were 
set at 150 ms and the interchannel delay at 50 ms. A multiple-reac-
tion monitoring (MRM) mode was applied for the quantification with 
the following parameters: m/z 854→286, collision energy at 20 eV 
for paclitaxel; and m/z 859→291, collision energy at 20 eV for the 
internal standard, paclitaxel-d5. The collision cell pressure was set 
at approximately 4 × 10–3 mbar (argon). Samples for the quantifica-
tion of paclitaxel were prepared by extraction of 100-μl aliquots with 
200 μl of an acetonitrile solution of the internal standard, and 1 ml 
of n-butylchloride. After vigorous mixing and centrifugation for 10 
minutes at 18,000 g, the clear supernatant was evaporated at a tem-
perature of 70°C. The residue was dissolved in 150 μl of a mixture 
of acetonitrile/water/formic acid (40:60:0.1, v/v/v), from which ali-
quots of 5 μl were injected into the LC/MS/MS system. The lower 
limit of quantification (LLQ) for paclitaxel was determined to be 
20.0 ng/ml, and the calibration curve ranged from 20.0 to 1,000 ng/
ml. The within-run and between-run precisions were within 7.14%, 
while the accuracy ranged from 88.5% to 94.1%.
Anesthesia. For the neurophysiological recordings, anesthesia was 
induced with 3% isoflurane carried in oxygen followed by 1% isoflu-
rane through a nose cone for maintenance throughout the procedures. 
This was adequate to suppress the corneal blink response and any 
withdrawal response to a noxious stimulus. The body temperature was 
maintained at 37°C using a heating pad (ATC-2000, World Precision 
Instruments) to minimize isoflurane-induced hypothermia.
Experimental design of neurotoxicity studies. The wild-type and 
OATP1B2–/– mice were randomly divided into 2 groups based on base-
line neurophysiology results (see below); one group was treated with 
paclitaxel only, and the other group was pretreated with nilotinib, 
30 minutes before paclitaxel. Mice were examined daily for sickness 
symptoms due to drug treatment. Changes in their appearance (e.g., 
kyphosis and altered grooming), behavior (e.g., altered nesting), and/
or activity (e.g., altered exploring) were monitored. Body weight was 
recorded before treatment and at least once a week for general toxic-
ity assessment and drug dose adjustment if indicated. Acute toxicities 
were evaluated following a single i.v. dose of paclitaxel (10 mg/kg), 
formulated in Cremophor EL/ethanol (1:1, v/v). In a separate set of 
experiments, acute toxicities were evaluated following a single i.v. dose 
of the paclitaxel metabolites 6α-hydroxy-paclitaxel (Toronto Research 
Chemicals; catalog H948890), 3′-p-hydroxy-paclitaxel (Toronto 
Research Chemicals; catalog H948895), or 6α,3′-p-dihydroxy-
paclitaxel (Toronto Research Chemicals; catalog D454200), all for-
mulated in Cremophor EL/ethanol (1:1, v/v) and administered at a 
dose of 10 mg/kg. In select experiments, single doses of nilotinib (100 
mg/kg; per os [p.o.]), rifampin (20 mg/kg; i.p.), pazopanib (20 mg/
kg; p.o.), or sorafenib (20 mg/kg; p.o.) were administered 30 minutes 
before the administration of paclitaxel.
For chronic toxicities, paclitaxel was administered once every 
week for 4 weeks at an i.v. dose of paclitaxel, formulated in a mixture 
of polysorbate 80/ethanol (1:1, v/v), preceded by nilotinib (100 mg/
kg; p.o.) or its vehicle (0.5% methylcellulose in water). Preliminary 
dose-response studies (60, 70, or 80 mg/kg) indicated that a weekly 
paclitaxel dose of 70 mg/kg in wild-type DBA/1LacJ mice produced 
neuropathy phenotypes, in particular decreases in the distal maximal 
action potential amplitudes (AMP) but not in digital nerve conduc-
tance velocity (NCV) (Supplemental Figure 7), that were quantitatively 
and qualitatively similar to those reported previously in other mouse 
strains such as nude-Foxn1nu (4).
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on liver samples (Supplemental Figure 8). The antibodies for phos-
pho-c-Abl (Tyr245) and total c-Abl were obtained from Cell Signaling 
Technology (catalog 07-787 and 2862, respectively).
Real-time PCR. Expression of transporter genes was analyzed with 
RT2 Profiler PCR arrays (SABiosciences), as described previously (56). 
Gene expression analyses in human tumors were based on the Pan 
Cancer gene expression data set (57), and extracted using the UCSC 
Xena browser. Tissue plates containing cDNA from 48 human breast 
cancer tissues (Tissue Scan Arrays BCRT-303) were obtained from 
Origene. RNA was reverse transcribed using SuperScript III First-
Strand Synthesis SuperMix for Real-Time PCR (Invitrogen), accord-
ing to the manufacturer’s recommendations. Gene transcripts were 
quantified using TaqMan Universal PCR Master Mix (Thermo Fisher 
Scientific) and primers obtained from Origene that were specific for 
OATP1B1 (HP209396) and OATP1B3 (HP213461). Reactions were 
carried out in triplicate as previously reported (41). Transcripts of each 
sample were normalized to the housekeeping gene, GAPDH.
Statistics. All data are presented as mean values and SD, unless 
stated otherwise. All experiments were performed independently on 
at least 2 separate occasions. An unpaired 2-sided Student’s t test with 
Welch’s correction or 1-way analysis of variance with a Dunnett post-
hoc test was used to evaluate statistical significance, using P less than 
0.05 as the cutoff.
Study approval. All animals were housed and handled in accor-
dance with the Institutional Animal Care and Use Committee of The 
Ohio State University, and all studies were performed in accordance 
with national animal protection laws.
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Neurophysiological analyses. Nerve conduction studies were per-
formed as previously described using a clinical electrodiagnostic sys-
tem (Ultra Pro S100, Natus Neurology) (4). Briefly, 2 needle electrodes 
(Natus Neurology) were placed near the fourth digit to stimulate the 
digital nerve, and 2 recording electrodes (ADD Company) were placed 
10 mm proximally. A total of 10 supramaximal stimulations were deliv-
ered, and the peak-to-peak compound AMP was obtained and averaged. 
All the neurophysiological recordings were performed with mice under 
isoflurane anesthesia delivered via nose cone in a temperature/humid-
ity controlled room. Body temperature was continuously monitored and 
maintained during the recordings. The baseline recordings were mea-
sured before starting the drug treatments in order to randomize animals 
into homogeneous groups. Because of interexperimental variability in 
baseline readings of AMP and NCV across the various studies, these 
parameters were always normalized to a value of 100%.
Mechanical threshold assessments. The nocifensive behaviors 
(hind paw flinching) after mechanical stimulation (Von Frey test) 
(41) was used to assess the development of mechanical allodynia, 
as previously described (4). A servo-controlled mechanical stimula-
tor with a blunt metallic filament (0.5 mm diameter) was positioned 
under the surface of the hind paw to exert a progressively increasing 
punctate pressure with a gram force ramp of 1 g/s. Thermal hyperal-
gesia (Hargreaves test) was evaluated with a dynamic esthesiometer 
(model 390, IITC Life Science) (55). On the day of testing, mice were 
placed in a Plexiglas chamber for 45 minutes to acclimate. When a 
spontaneous hind paw withdrawal occurred, the stimulus was auto-
matically stopped and the gram force of the pressure or the time to 
withdrawal was recorded. This was assessed alternately on each hind 
paw every 2 minutes for 3 consecutive trials to obtain a mean value 
of the maximal pressure (expressed in grams) or heat tolerated by the 
mice. To prevent tissue damage, an upper cutoff limit of 15 g or 20 
seconds was set, after which the increasing mechanical or thermal 
stimulus was terminated.
Evaluation of antitumor efficacy. Accumulation of paclitaxel lev-
els in breast cancer cell lines was determined as described above 
for transfected HEK293 cells at a concentration of 2 μM (5-minute 
uptake) in the presence or absence of nilotinib (15-minute preincu-
bation with 10 μM or vehicle). For in vitro uptake and cytotoxicity 
studies, stock solutions of nilotinib and paclitaxel were prepared 
with the drugs dissolved in DMSO. The cell growth inhibitory 
potential was evaluated with an MTT assay using 72-hour continu-
ous exposure. The influence of nilotinib (1 or 10 μM or vehicle; 
15-minute preincubation) on the cytotoxicity of paclitaxel (range, 
0.00001–50 μM) was evaluated in the replicating breast cancer cell 
lines MDA-MB-468, MCF-7, T-47D, MDA-MB-231, and HS-578T 
(National Cancer Institute, NIH).
Immunohistochemistry and immunoblotting. Protein expression 
analyses on isolated liver and DRG samples from wild-type and OAT-
P1B2–/– mice were performed as described previously (41). For immu-
nohistochemistry, a previously validated OATP1B2 primary antibody 
was provided by Curtis D. Klaassen and Iván L. Csanaky (University 
of Kansas Medical Center, Kansas City, Kansas, USA), and Alexa Fluor 
647 goat anti–rabbit IgG (H+L) (Invitrogen, A21244, lot 1871168) was 
used as a secondary antibody. For immunoblotting, the same primary 
antibody was used and peroxidase-conjugated AffiniPure rabbit anti–
mouse IgG (H+L) (Jackson ImmunoResearch, catalog 315-035-045, 
lot 119936) as a secondary antibody, and the procedure was validated 
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